Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology

Cancer Research

Volumn 72, Issue 1, 2012, Pages 3-12

  Gao, Jin ^a   Chang, Yong S ^a,b   Jallal, Bahija ^a   Viner, Jaye ^a  

^a MEDIMMUNE   (United States)

^b Aileron Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AVE 1642; BIIB 022; CARBOPLATIN; CETUXIMAB; CIXUTUMUMAB; CONATUMUMAB; DALOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; EVEROLIMUS; FIGITUMUMAB; GANITUMAB; GEMCITABINE; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; IRINOTECAN; MEDI 573; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; CANCER GROWTH; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL CANCER; DECREASED APPETITE; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG RESEARCH; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; EWING SARCOMA; FATIGUE; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; LIVER CELL CARCINOMA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; ONCOLOGY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SOLID TUMOR; THYMOMA; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; SOMATOMEDINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855398829     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0550     Document Type: Review

References (41)

1. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010;28: 4985-95.
2. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007;13:671-86. (Pubitemid 46510744)
3. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
4. Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008;12:589-603. (Pubitemid 351699478)
5. Hendrickson AW, Haluska P. Resistance pathways relevant to insulinlike growth factor-1 receptor-targeted therapy. Curr Opin Investig Drugs 2009;10:1032-40.
6. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol Neoplasia 2008;13:471-83.
7. Vasilcanu D, Weng WH, Girnita A, Lui WO, Vasilcanu R, Axelson M, et al. The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. Oncogene 2006;25:3186-95. (Pubitemid 43881559)
8. Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, et al. Dual IGF-I/II-neutralizing antibody MEDI- 573 potently inhibits IGF signaling and tumor growth. Cancer Res 2011;71:1029-40.
9. Massoner P, Colleselli D, Matscheski A, Pircher H, Geley S, Jansen Dürr P, et al. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility. Endocr Relat Cancer 2009;16:795-808.
10. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010;11:129-35.
11. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010;65:765-73.
12. Lacy MQ,Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, et al. Phase I, pharmacokinetic and pharmacodynamic study of the antiinsulin like growth factor type 1 Receptor monoclonal antibody CP- 751,871 in patients with multiple myeloma. J Clin Oncol 2008;26:3196-203.
13. Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP- 751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010;103:332-9.
14. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-22.
15. Karp DD, Novello S, Cardenal F, Haluska P, Blakely LJ, Garland L, et al. Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. J Clin Oncol 2009;27:15s (abstr 8072).
16. Hixon ML, Gualberto A, Demers L, Paz-Ares LG, Novello S, Blakely LJ, et al. Correlation of plasma levels of free insulin-like growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP- 751, 871). J Clin Oncol 2009;27:15s (abstr 3539).
17. Jassem J, Langer CJ, Karp DD, Mok T, Benner RJ, Green SJ, et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28:15s (abstr 7500).
18. Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011;17:871-9.
19. Higano CS, Alumkal JJ, Ryan CJ, Yu EY, Beer TM, Fox FE, et al. A phase II study of cixutumumab (IMC-A12), a monoclonal antibody (mAb) against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-resistant prostate cancer (mCRPC): Feasibility of every 3-week dosing and updated results. Genitourinary Cancers Symposium, 2010; San Francisco, CA, USA. Abstr 189.
20. Rajan A, Berman AW, Kelly RJ, Lopez-Chavez A, Dechowdhury R, Chen H, et al. Phase II study of the insulin-like growth factor-1 receptor (IGF-1R) antibody cixutumumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC). J Clin Oncol 2010;28:15s (e17525).
21. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-7.
22. Puzanov I, Sarantopoulos J, Gilbert J, Mahalingam D, Chap LI, Deng H, et al. Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors. J Clin Oncol 2010;28:15s (abstr 3018).
23. Chawla SP, Tabernero J, Kindler HL, Chiorean EG, LoRusso P, Hsu M, et al. Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors. J Clin Oncol 2010;28:15s (abstr 3102).
24. Sarantopoulos J, Mita AC, Mulay M, Romero O, Lu J, Capilla F, et al. A phase IB study ofAMG479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) orgemcitabine (G). J Clin Oncol 2008;26:abstr 3583.
25. Tap WD, Demetri GD, Barnette P, Desai J, Kavan P, Tozer R, et al.AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results. J Clin Oncol 2010;28:15s (abstr 10001).
26. Lu J, Deng H, Tang R, Hsu C, Kindler HL, Fuchs C, et al. Exposureresponse (E-R)analysis tofacilitate phase III (P3) dose selection forAMG 479 (A479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC). J Clin Oncol 2011;29 (suppl 4; abstr 263).
27. Atzori F, Tabernero J, Cervantes A, Botero M, Hsu K, Brown H, et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (mAb) in patients (pts) with advanced solid tumors. J Clin Oncol 2008;26: abstr 3519.
28. Moran T, Felip-Font E, Torres JM, Borghaei H, Fitzgerald T, Clark J, et al. An open label, randomized ph I/IIa trial evaluating MK-0646, an anti-IGF-1R monoclonal antibody, in combination with erlotinib for patients with recurrent non-small cell lung cancer. 100th Annual Meeting of the American Association for Cancer Research. Denver, CO, USA, 18-22 April 2009 (abstr 5622).
29. Watkins DJ, Tabernero J, Schmoll HJ, Trarbach T, Ramos FJ, Hsu K, et al. A phase II study of the anti-IGFR antibody MK-0646 in combination with cetuximab and irinotecan in the treatment of chemorefractory metastatic colorectal cancer. J Clin Oncol 2009;27:15s (abstr 4127).
30. Javle MM, Varadhachary GR, Shroff RT, Bhosale P, Overman MJ, Weatherly J, et al. Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. J Clin Oncol 2010;28:15s (abstr 4039).
31. Faivre SJ, Fartoux L, Bouattour M, Bumsel F, Dreyer C, Raymond E, et al. A phase I study of AVE1642, a human monoclonal antibodyblocking insulin-like growth factor-1 receptor (IGF-1R), given as a single agent and in combination with sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011;29: (suppl 4; abstr 270).
32. vonMehren M, BrittenC, Lear K,CamidgeDR, Wainberg ZA, Pieslor PC, et al.Phase I,dose-escalationstudy of BIIB022(anti-IGF-1Rantibody) in advanced solid tumors. J Clin Oncol 2010;28:15s (abstr 2612).
33. Menefee M, LoRusso P, Viner J, McDevitt J, Huang W, Lam B, et al. MEDI-573, a dual IGF-1/-2 neutralizing antibody, blocks IGF-1R and IR-A signaling and maintains glucose homeostasis in a Phase 1 study for advanced solid tumors. In: Proceedings of the 22nd EORTCNCI- AACR Symposium, 2010 November 16-19; Berlin, Germany. Philadelphia (PA): AACR; Abstr 3LB.
34. Olmos D, Martins AS, Jones RL, Alam S, Scurr M, Judson IR. Targeting the insulin-like growth factor 1 receptor in Ewing's sarcoma: reality and expectations. Sarcoma 2011:e pub 402508.
35. Watkins DJ, Tabernero J, Schmoll H, Trarbach T, Ramos FJ, Howe J, et al. A randomized phase II/III study of the anti-IGF-1R antibody MK- 0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status. J Clin Oncol 2011;29: abstr 3501.
36. Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, et al. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 2011; 104:68-74.
37. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011;30:2730-40.
38. Baserga R. The insulin receptor substrate-1: a biomarker for cancer? Exp Cell Res 2009;315:727-32.
39. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-71.
40. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008;26:4078-85.
41. Belfiore A, Frasca F. IGFand insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:381-406.